Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis

USA - NASDAQ:ADXN - US00654J2069 - ADR

9.2 USD
-0.19 (-2.02%)
Last: 10/3/2025, 8:21:04 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ADXN. ADXN was compared to 197 industry peers in the Pharmaceuticals industry. The financial health of ADXN is average, but there are quite some concerns on its profitability. ADXN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ADXN was profitable.
In the past year ADXN has reported a negative cash flow from operations.
ADXN had negative earnings in 4 of the past 5 years.
In the past 5 years ADXN always reported negative operating cash flow.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

ADXN has a better Return On Assets (95.59%) than 99.49% of its industry peers.
ADXN has a better Return On Equity (109.29%) than 99.49% of its industry peers.
Industry RankSector Rank
ROA 95.59%
ROE 109.29%
ROIC N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin of ADXN (1410.05%) is better than 99.49% of its industry peers.
ADXN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 1410.05%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

4

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADXN has been increased compared to 1 year ago.
Compared to 5 years ago, ADXN has more shares outstanding
The debt/assets ratio for ADXN has been reduced compared to a year ago.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -44.37, we must say that ADXN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -44.37, ADXN is doing worse than 88.83% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ADXN is not too dependend on debt financing.
The Debt to Equity ratio of ADXN (0.00) is better than 60.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.37
ROIC/WACCN/A
WACC4.99%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 3.03 indicates that ADXN has no problem at all paying its short term obligations.
ADXN has a Current ratio (3.03) which is in line with its industry peers.
A Quick Ratio of 3.03 indicates that ADXN has no problem at all paying its short term obligations.
ADXN has a Quick ratio (3.03) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

ADXN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 168.16%, which is quite impressive.
Looking at the last year, ADXN shows a very negative growth in Revenue. The Revenue has decreased by -53.40% in the last year.
The Revenue for ADXN have been decreasing by -32.07% on average. This is quite bad
EPS 1Y (TTM)168.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-53.4%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-70.6%

3.2 Future

The Earnings Per Share is expected to decrease by -16.99% on average over the next years. This is quite bad
Based on estimates for the next years, ADXN will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.99%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.87, the valuation of ADXN can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of ADXN indicates a rather cheap valuation: ADXN is cheaper than 98.98% of the companies listed in the same industry.
ADXN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
ADXN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.87
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

ADXN's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (10/3/2025, 8:21:04 PM)

9.2

-0.19 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-30 2025-09-30
Earnings (Next)11-10 2025-11-10
Inst Owners1.32%
Inst Owner Change-98.18%
Ins Owners7.07%
Ins Owner ChangeN/A
Market Cap9.83M
Analysts40
Price Target7.61 (-17.28%)
Short Float %10.76%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-16.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.87
Fwd PE N/A
P/S 12.18
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)10.56
EY114.78%
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-4.08
FCFYN/A
OCF(TTM)-4.08
OCFYN/A
SpS0.76
BVpS9.75
TBVpS9.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 95.59%
ROE 109.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1410.05%
GM N/A
FCFM N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z -44.37
F-Score6
WACC4.99%
ROIC/WACCN/A
Cap/Depr(3y)0.97%
Cap/Depr(5y)5.54%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.99%
Revenue 1Y (TTM)-53.4%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-70.6%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y71.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.67%
EBIT Next 3Y5.45%
EBIT Next 5Y5.93%
FCF growth 1Y75.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.11%
OCF growth 3YN/A
OCF growth 5YN/A